Related Experiment Videos
Risk-benefit analysis for drotrecogin alfa (activated).
Roland M H Schein1, Gary T Kinasewitz
1Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, Critical Care Medicine (III), 11300 Northeast Second Avenue, Miami Shore, FL 33125, USA. rschein@med.miami.edu
American Journal of Surgery
|January 11, 2003
Summary
Drotrecogin alfa (activated) reduces mortality in severe sepsis patients. However, this recombinant human coagulation inhibitor increases bleeding risk, necessitating careful risk-benefit assessment for optimal patient care.
Area of Science:
- Critical care medicine
- Pharmacology
- Hematology
Background:
- Risk-benefit analysis is crucial in patient care.
- Drotrecogin alfa (activated) is a novel recombinant human coagulation inhibitor.
- Severe sepsis treatment requires careful consideration of risks and benefits.
Purpose of the Study:
- To analyze the risks and benefits of drotrecogin alfa (activated) therapy.
- To evaluate the survival benefits in patients with severe sepsis.
- To discuss potential risks, including bleeding, associated with the treatment.
Main Methods:
- Review of clinical data on drotrecogin alfa (activated) in severe sepsis.
- Analysis of safety profiles, focusing on bleeding events.
- Evaluation of efficacy in reducing mortality.
Main Results:
- Drotrecogin alfa (activated) significantly reduces the risk of death in severe sepsis.
- The therapy is associated with an increased risk of bleeding.
- Careful patient selection is implied for optimal outcomes.
Conclusions:
- Drotrecogin alfa (activated) offers survival benefits for severe sepsis patients.
- Bleeding risk must be weighed against survival advantages.
- Informed clinical decision-making is essential for this therapy.